Navigation Links
Simcere Pharmaceutical Group Seeking Approval to Manufacture and Sell Influenza Drug zanamivir
Date:5/6/2009

NANJING, China, May 6 /PRNewswire-Asia/ -- Simcere Pharmaceutical Group (NYSE: SCR), a leading manufacturer and supplier of branded generic and innovative anti-cancer pharmaceuticals in China, announced today that the Company is seeking approval to manufacture and sell products containing zanamivir, one of only two WHO approved drugs to which the new H1N1 strain of influenza A has been shown to be susceptible.

GlaxoSmithKline granted a license to Simcere in 2006 to make products containing zanamivir. Simcere is the only pharmaceutical company in mainland China that has such a license.

"We look forward to obtaining the approval to manufacture and sell zanamivir in China. To this end, we have already begun to prepare the raw materials and manufacturing facilities required to launch this drug," commented Mr. Xiaojin Yin, Senior Vice President of Research and Development of Simcere Pharmaceutical Group.

About Simcere Pharmaceutical Group

Simcere Pharmaceutical Group (NYSE: SCR, Simcere) is a leading manufacturer and supplier of branded generic and innovative pharmaceuticals in China. In recent years, Simcere has been focusing its strategy on the development of innovative pharmaceuticals and first-to-market generics, and has introduced an innovative anti-cancer medication Endu, a first-to-market medication Sinofuan, and first-to-market generics such as Bicun and Anxin. Simcere manufactures and sells antibiotics, anti-cancer medication and stroke management medication. Simcere concentrates its research and development efforts on the treatment of diseases with high incidence and/or mortality rates and for which there is a clear demand for more effective pharmacotherapy such as cancer, strokes, orthopaedics and infectious diseases. For more information about Simcere Pharmaceutical Group, please visit http://www.simcere.com .


'/>"/>
SOURCE Simcere Pharmaceutical Group
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Simcere Pharmaceutical Group Acquires a 51% Stake in Boda Pharmaceutical Co., Ltd.
2. Simcere Pharmaceutical Group Reports Third Quarter 2007 Results
3. Simcere Pharmaceutical Group to Announce Fourth Quarter 2007 Earnings on Tuesday, March 4, 2008
4. Simcere Pharmaceutical Group Reports Unaudited Fourth Quarter and Fiscal Year 2007 Results
5. Simcere Pharmaceutical Group Announces Participation in Brean Murray Carret & Co.s Fourth Investor Tour of China
6. Simcere Pharmaceutical Group to Announce First Quarter 2008 Earnings on Tuesday, May 6, 2008
7. Simcere Pharmaceutical Group Acquires 70% Stake in Wuhu Zhong Ren Pharmaceutical Co. Ltd.
8. Simcere Pharmaceutical Group Announces SFDA Approval of First-to-Market Generic Biapenem Injection Anxin
9. Simcere Pharmaceutical Group Reports Unaudited Second Quarter 2008 Results
10. Simcere Pharmaceutical Group to Participate in Goldman Sachs China Investment Frontier Conference 2008
11. Mylan Commences Tender Offers and Consent Solicitations for Its 5.750% Senior Notes Due 2010 and 6.375% Senior Notes Due 2015 in Connection With Its Proposed Acquisition of Mercks Generic Pharmaceutical Business
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/11/2016)... , ... February 11, 2016 , ... ... dermatology and women’s health, is pleased to announce the promotions of Allison Kelly ... sales team, Steve Catone to executive vice president of North American capital sales, ...
(Date:2/11/2016)... , ... February 11, 2016 , ... ... unparalleled clinical decision support technology, with highly adaptable algorithms, has been updated to ... patient has signs and symptoms consistent with Zikas and a travel history to ...
(Date:2/11/2016)... , ... February 11, 2016 , ... ... J.R. Garrett Esq. as General Counsel. Garrett will focus on contract negotiations, corporate ... audits, privacy and security law, and best practices in data breaches for the ...
(Date:2/11/2016)... ... ... Colorado spine surgeon, Donald Corenman, MD, DC has been selected ... 2016 . The list consists of spine surgeons across the country nominated by their ... the importance of clinical excellence; he has been awarded the Patient’s Choice Award, Compassionate ...
(Date:2/11/2016)... ... February 11, 2016 , ... Duterte Insurance ... involvement program, introduces a new charity campaign to raise funds for Ronald McDonald ... accepted at https://donate.rmhc.org/ . , Ronald McDonald House (RMH) is an internationally ...
Breaking Medicine News(10 mins):
(Date:2/11/2016)... BURLINGAME, Calif. , Feb. 11, 2016  NOIT™ ... announced a special "Gift of Change" campaign to assist ... units. For every such unit sold between February 10, ... a unit to a needy family. The NOIT is ... helping non/limited-verbal autistic individuals develop language skills. ...
(Date:2/11/2016)... Ore. , Feb. 11, 2016 Wellpartner, ... announce the acquisition of SolutionsRx, a full-service 340B company ... Along with providing traditional contract pharmacy services, SolutionsRx also ... clients in navigating the complex 340B regulatory environment. ... --> James R. Love , CEO of ...
(Date:2/11/2016)... Transformational M&A achieved through NPS and Dyax acquisitions ... Transformational M&A achieved through NPS and Dyax acquisitions and the ... M&A achieved through NPS and Dyax acquisitions and the announced ... with most robust pipeline in Shire , s ... most robust pipeline in Shire , s history ...
Breaking Medicine Technology: